---
figid: PMC6613878__svn-2018-000199f01
figlink: /pmc/articles/PMC6613878/figure/F1/
number: F1
caption: 'Therapeutic strategies targeting NAMPT against stroke. There are two ways
  to maintain the cellular NAD level in mammals: the de novo pathway from tryptophan
  and the salvage pathway from NAM, NR and NA with different catalysing enzymes. NAMPT
  is the rate-limiting enzyme of NAD synthesis in the salvage pathway, thereby influencing
  NAD-dependent enzymes and regulating cellular metabolism, mitochondrial biogenesis
  and the adaptive response to inflammatory, oxidative, proteotoxic and genotoxic
  stresses. Accumulating in-vitro and in-vivo studies indicate that NAMPT is a therapeutic
  target against stroke from five potential therapeutic strategies: NAMPT overexpression,
  recombinant NAMPT, NAMPT activators, NAMPT enzymatic product NMN, NMN precursors
  NR and NAM. In ischaemic stroke, targeting NAMPT can confer neuroprotection via
  regulating mitochondrial biogenesis, activating SIRT1, inhibiting PARP1 activity
  and mimicking IPC. And, NAMPT related treatment exerts biological function in EPCs
  and NSCs to promote neovascularization and neurogenesis after ischaemic stroke.
  Remarkably, there is positive evidence of NAMPT in ICH, wherein NMN treatment can
  attenuate brain injury by activating Nrf2/HO-1 signalling pathway in the mouse model
  of cICH, and protect BBB integrity and attenuate brain infarction and haemorrhage
  in the mouse model of tPA-ICH, indicating NAMPT mediated neuroprotection in ICH.
  These preclinical evidences indicate targeting NAMPT can be a promising choice for
  developing novel and effective therapeutic interventions against stroke. BBB, blood–brain
  barrier; cICH, collagenase-induced intracerebral haemorrhage; EPCs, endothelial
  progenitor cells; IPC, ischaemic preconditioning; NA, nicotinic acid; NAD, nicotinamide
  adenine dinucleotide; NAM, nicotinamide; NAMN, nicotinic acid mononucleotide; NAMPT,
  nicotinamide phosphoribosyltransferase; NAPRT, nicotinic acid phosphoribosyltransferase;
  NMN, nicotinamide mononucleotide; NMNAT, nicotinamide mononucleotide adenylyltransferase;
  NR, nicotinamide riboside; NRK, nicotinamide ribose kinase; NSCs, neural stem cells;
  PARPs, poly-ADP-ribose polymerases; QAPRT, quinolinate phosphoribosyltransferase;
  SIRTs, sirtuins; tPA-ICH, tPA-induced cerebral infarction haemorrhagic transformation.'
pmcid: PMC6613878
papertitle: Targeting NAMPT as a therapeutic strategy against stroke.
reftext: Shu-Na Wang, et al. Stroke Vasc Neurol. 2019 Jun;4(2):83-89.
pmc_ranked_result_index: '31465'
pathway_score: 0.8873491
filename: svn-2018-000199f01.jpg
figtitle: Therapeutic strategies targeting NAMPT against stroke
year: '2019'
organisms:
- Homo sapiens
ndex: fb6878b3-df10-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6613878__svn-2018-000199f01.html
  '@type': Dataset
  description: 'Therapeutic strategies targeting NAMPT against stroke. There are two
    ways to maintain the cellular NAD level in mammals: the de novo pathway from tryptophan
    and the salvage pathway from NAM, NR and NA with different catalysing enzymes.
    NAMPT is the rate-limiting enzyme of NAD synthesis in the salvage pathway, thereby
    influencing NAD-dependent enzymes and regulating cellular metabolism, mitochondrial
    biogenesis and the adaptive response to inflammatory, oxidative, proteotoxic and
    genotoxic stresses. Accumulating in-vitro and in-vivo studies indicate that NAMPT
    is a therapeutic target against stroke from five potential therapeutic strategies:
    NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product
    NMN, NMN precursors NR and NAM. In ischaemic stroke, targeting NAMPT can confer
    neuroprotection via regulating mitochondrial biogenesis, activating SIRT1, inhibiting
    PARP1 activity and mimicking IPC. And, NAMPT related treatment exerts biological
    function in EPCs and NSCs to promote neovascularization and neurogenesis after
    ischaemic stroke. Remarkably, there is positive evidence of NAMPT in ICH, wherein
    NMN treatment can attenuate brain injury by activating Nrf2/HO-1 signalling pathway
    in the mouse model of cICH, and protect BBB integrity and attenuate brain infarction
    and haemorrhage in the mouse model of tPA-ICH, indicating NAMPT mediated neuroprotection
    in ICH. These preclinical evidences indicate targeting NAMPT can be a promising
    choice for developing novel and effective therapeutic interventions against stroke. BBB,
    blood–brain barrier; cICH, collagenase-induced intracerebral haemorrhage; EPCs,
    endothelial progenitor cells; IPC, ischaemic preconditioning; NA, nicotinic acid;
    NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMN, nicotinic acid
    mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NAPRT, nicotinic
    acid phosphoribosyltransferase; NMN, nicotinamide mononucleotide; NMNAT, nicotinamide
    mononucleotide adenylyltransferase; NR, nicotinamide riboside; NRK, nicotinamide
    ribose kinase; NSCs, neural stem cells; PARPs, poly-ADP-ribose polymerases; QAPRT,
    quinolinate phosphoribosyltransferase; SIRTs, sirtuins; tPA-ICH, tPA-induced cerebral
    infarction haemorrhagic transformation.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NOTCH1
  - NOTCH2
  - NOS3
  - PRKAB2
  - PRKAB1
  - PRKAG2
  - PRKAG3
  - PRKAG1
  - CD38
  - MTOR
  - NAMPT
  - BAX
  - NMNAT1
  - NOTCH4
  - PRKAA1
  - PRKAA2
  - NRK
  - PARP1
  - NOTCH3
  - HMOX1
  - NAPRT
  - TSC2
  - NT5E
  - SIRT2
  - SIRT6
  - SIRT1
  - ATP
  - NAMPT
  - NAD
  - Glutamate
  - Stroke
  - stroke
  - Hemorrhagic stroke
  - CICH
  - ICH
  - Infarction
  - hemorrhage
  - inflammation
genes:
- word: Notch/ENOS
  symbol: Notch
  source: bioentities_symbol
  hgnc_symbol: NOTCH1
  entrez: '4851'
- word: Notch/ENOS
  symbol: Notch
  source: bioentities_symbol
  hgnc_symbol: NOTCH2
  entrez: '4853'
- word: Notch/ENOS
  symbol: eNOS
  source: hgnc_alias_symbol
  hgnc_symbol: NOS3
  entrez: '4846'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: CD38
  symbol: CD38
  source: hgnc_symbol
  hgnc_symbol: CD38
  entrez: '952'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: NAMPT
  symbol: NAMPT
  source: hgnc_symbol
  hgnc_symbol: NAMPT
  entrez: '10135'
- word: Bax/bel-2
  symbol: BAX
  source: hgnc_symbol
  hgnc_symbol: BAX
  entrez: '581'
- word: NMNAT
  symbol: NMNAT
  source: hgnc_alias_symbol
  hgnc_symbol: NMNAT1
  entrez: '64802'
- word: Notch/ENOS
  symbol: Notch
  source: bioentities_symbol
  hgnc_symbol: NOTCH4
  entrez: '4855'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: NRK
  symbol: NRK
  source: hgnc_symbol
  hgnc_symbol: NRK
  entrez: '203447'
- word: PARP1
  symbol: PARP1
  source: hgnc_symbol
  hgnc_symbol: PARP1
  entrez: '142'
- word: Notch/ENOS
  symbol: Notch
  source: bioentities_symbol
  hgnc_symbol: NOTCH3
  entrez: '4854'
- word: Nrf2/HO-1
  symbol: HO-1
  source: hgnc_alias_symbol
  hgnc_symbol: HMOX1
  entrez: '3162'
- word: NAPRT
  symbol: NAPRT
  source: hgnc_symbol
  hgnc_symbol: NAPRT
  entrez: '93100'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: CD73
  symbol: CD73
  source: hgnc_alias_symbol
  hgnc_symbol: NT5E
  entrez: '4907'
- word: SIRT2
  symbol: SIRT2
  source: hgnc_symbol
  hgnc_symbol: SIRT2
  entrez: '22933'
- word: SIRT6
  symbol: SIRT6
  source: hgnc_symbol
  hgnc_symbol: SIRT6
  entrez: '51548'
- word: SIRT1
  symbol: SIRT1
  source: hgnc_symbol
  hgnc_symbol: SIRT1
  entrez: '23411'
chemicals:
- word: ATP
  source: MESH
  identifier: D000255
- word: NAMPT
  source: MESH
  identifier: C085455
- word: NAD
  source: MESH
  identifier: D009243
- word: Glutamate
  source: ''
  identifier: ''
diseases:
- word: Stroke
  source: MESH
  identifier: D020521
- word: stroke
  source: MESH
  identifier: D020521
- word: Hemorrhagic stroke
  source: MESH
  identifier: D020521
- word: CICH
  source: ''
  identifier: ''
- word: ICH
  source: MESH
  identifier: D002543
- word: Infarction
  source: MESH
  identifier: D007238
- word: hemorrhage
  source: MESH
  identifier: D006470
- word: inflammation
  source: MESH
  identifier: D007249
figid_alias: PMC6613878__F1
redirect_from: /figures/PMC6613878__F1
figtype: Figure
---
